Behranwala K A, Nasiri N, Abdullah N, Trott P A, Gui G P H
Academic Surgery and Pathology Department (Breast Unit), Royal Marsden NHS Trust, London, UK.
Eur J Surg Oncol. 2003 May;29(4):386-9. doi: 10.1053/ejso.2002.1422.
Pure squamous cell carcinoma (SCC) of the breast is a rare tumour and little is known about long-term outcome. We report our experience of a consecutive series of patients.
All patients with SCC treated at our institution between 1970 and 2001 were included. The pathological features, outcome and prognosis were studied.
Eleven patients were identified. The median age was 55 (38-90) years and median follow-up was 62 (3-332) months. Four tumours were T1, three were T2 and three were T3 (one tumour size was unknown). There were seven poorly differentiated and three moderately differentiated SCC. Tumour grade could not be assessed in one patient. Primary treatment was mastectomy in six patients, wide local excision in four patients and radiotherapy in one patient. There was lymph node (LN) involvement in two patients. Oestrogen receptor status was assessed in seven patients and only one tumour was positive. Adjuvant chemotherapy was given to three patients and five patients received adjuvant radiotherapy. Two patients developed local recurrence at 5 and 12 months and three patients developed distant metastasis at 2, 36 and 306 months. Three patients were treated with chemotherapy at recurrence. Three patients have died of the disease, two are alive with disease and six remain well. The 2- and 5-year overall survival was 80% (SE=13%) and 67% (SE=16%) respectively. Large tumour size and positive LN status were prognostic indicators of poor outcome.
SCC of the breast adopts an aggressive course with outcome comparable to poorly differentiated breast adenocarcinoma.
乳腺纯鳞状细胞癌（SCC）是一种罕见肿瘤，对其长期预后了解甚少。我们报告一系列连续患者的经验。
纳入1970年至2001年在我院接受治疗的所有SCC患者。研究其病理特征、结局和预后。
共识别出11例患者。中位年龄为55（38 - 90）岁，中位随访时间为62（3 - 332）个月。4例肿瘤为T1期，3例为T2期，3例为T3期（1例肿瘤大小未知）。7例为低分化SCC，3例为中分化SCC。1例患者的肿瘤分级无法评估。6例患者的初始治疗为乳房切除术，4例为广泛局部切除，1例为放疗。2例患者有淋巴结（LN）转移。7例患者评估了雌激素受体状态，仅1例肿瘤呈阳性。3例患者接受辅助化疗，5例患者接受辅助放疗。2例患者分别在5个月和12个月出现局部复发，3例患者分别在2个月、36个月和306个月出现远处转移。3例复发患者接受了化疗。3例患者死于该疾病，2例带瘤生存，6例情况良好。2年和5年总生存率分别为80%（标准误 = 13%）和67%（标准误 = 16%）。肿瘤体积大及LN转移阳性是预后不良的指标。
乳腺SCC病程侵袭性强，预后与低分化乳腺腺癌相当。
